Last reviewed · How we verify

Small cell carcinoma of lung — Treatment Landscape & Competitive Intelligence

Small cell carcinoma of lung (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Small cell carcinoma of lung, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Zepzelca LURBINECTEDIN Jazz Pharmaceuticals Alkylating Drug [EPC] 2020-01-01
Imfinzi durvalumab AstraZeneca Programmed Death Ligand-1 Blocker [EPC] Programmed cell death 1 ligand 1 2017-01-01
Nogitecan topotecan Novartis topotecan ATP-binding cassette sub-family G member 2 1996-01-01
Vepesid etoposide Bristol-Myers Squibb K.K. Topoisomerase Inhibitor [EPC] DNA topoisomerase 2-alpha 1983-01-01
Doxorubicin Hydrochloride doxorubicin Pfizer Anthracycline Topoisomerase Inhibitor Aurora kinase A 1974-01-01
Liposomal Doxorubicin liposomal-doxorubicin Pfizer doxorubicin 72 kDa type IV collagenase 1974-01-01
Imfinzi Imfinzi University Medical Center Groningen Programmed cell death 1 ligand 1
Zepzelca Zepzelca Jazz Pharmaceuticals
Hycamtin Hycamtin North Eastern German Society of Gynaecological Oncology Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 4, ATP-binding cassette sub-family G member 2
Adriamycin Adriamycin Johann Wolfgang Goethe University Hospital Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Jazz Pharmaceuticals · 2 drugs in Small cell carcinoma of lung
  2. Pfizer · 2 drugs in Small cell carcinoma of lung
  3. Chipscreen Biosciences, Ltd. · 1 drug in Small cell carcinoma of lung
  4. Johann Wolfgang Goethe University Hospital · 1 drug in Small cell carcinoma of lung
  5. North Eastern German Society of Gynaecological Oncology · 1 drug in Small cell carcinoma of lung
  6. Novartis · 1 drug in Small cell carcinoma of lung
  7. University Medical Center Groningen · 1 drug in Small cell carcinoma of lung
  8. University of Colorado, Denver · 1 drug in Small cell carcinoma of lung
  9. University of Ulm · 1 drug in Small cell carcinoma of lung
  10. AstraZeneca · 1 drug in Small cell carcinoma of lung
  11. Weill Medical College of Cornell University · 1 drug in Small cell carcinoma of lung
  12. Bristol-Myers Squibb K.K. · 1 drug in Small cell carcinoma of lung

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Small cell carcinoma of lung:

Cite this brief

Drug Landscape (2026). Small cell carcinoma of lung — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/small-cell-carcinoma-of-lung. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing